On the Mechanism of Action of Antitoxoplasma Compound SW33
Advisor Information
Paul Davis, Ph.D.
Location
Room 112
Presentation Type
Oral Presentation
Start Date
1-3-2019 10:30 AM
End Date
1-3-2019 11:45 AM
Abstract
ON THE MODE OF ACTION OF ANTITOXOPLASMA COMPOUND SW33
Sean Watson, Austin Sanford, and Paul Davis, Department of Biology, University of Nebraska at Omaha.
As antimicrobial drug resistance continues to increase throughout the world, there lies an urgent need for the development of novel, efficacious drug treatments. As antimicrobial drugs are developed, their mode of action (MOA) is often identified before they become potential candidates for clinical use. Determining the MOA is important as it demonstrates the function of the drug at the cellular level and exposes potential risks for toxicity. One method to determine the MOA, termed chemical mutagenesis, consists of the induction of drug resistance in vitro followed by examination of the resistant population’s genomes to identify which genes are conferring resistance. In this work, I utilize the ubiquitous parasite Toxoplasma gondii to explore a novel method of double mutagenesis with the goal of determining the MOA of experimental compound SW33, a drug that has shown efficacy against both T. gondii and the causative agent of malaria, Plasmodium falciparum.
On the Mechanism of Action of Antitoxoplasma Compound SW33
Room 112
ON THE MODE OF ACTION OF ANTITOXOPLASMA COMPOUND SW33
Sean Watson, Austin Sanford, and Paul Davis, Department of Biology, University of Nebraska at Omaha.
As antimicrobial drug resistance continues to increase throughout the world, there lies an urgent need for the development of novel, efficacious drug treatments. As antimicrobial drugs are developed, their mode of action (MOA) is often identified before they become potential candidates for clinical use. Determining the MOA is important as it demonstrates the function of the drug at the cellular level and exposes potential risks for toxicity. One method to determine the MOA, termed chemical mutagenesis, consists of the induction of drug resistance in vitro followed by examination of the resistant population’s genomes to identify which genes are conferring resistance. In this work, I utilize the ubiquitous parasite Toxoplasma gondii to explore a novel method of double mutagenesis with the goal of determining the MOA of experimental compound SW33, a drug that has shown efficacy against both T. gondii and the causative agent of malaria, Plasmodium falciparum.